About this episode

This episode discusses the evolution of gene editing and biologics manufacturing with industry experts.

In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jack Crawford , CEO, Demeetra Magnus Gustafsson , Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Jack Crawford, Magnus Gustavsson

Topics covered

• gene editing
• biologics manufacturing
• cell line development
• CHO cells
• transposases
• GMP

Keywords

• gene editing
• biologics
• cell line development
• CHO cells
• transposases
• GMP
• collaboration models

Mentioned in this episode

Organizations: Demetra, NorthX Biologics

More episodes of BioSpace

• The future of pain relief: Exploring opioid alternatives · July 16, 2026 · 19 min
• Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup · July 15, 2026 · 21 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water · July 1, 2026 · 23 min
• The Golden Triangle and the gaps: Rethinking UK biotech · June 25, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.